Literature DB >> 7239117

Cimetidine impairs the elimination of theophylline and antipyrine.

R K Roberts, J Grice, L Wood, V Petroff, C McGuffie.   

Abstract

In 7 healthy subjects theophylline and antipyrine elimination were determined before and during a course of oral cimetidine in a dose of 1 g/day. Plasma clearance of theophylline was reduced from 71.2 +/- 10.1 ml/min to 56.0 +/- 18.5 ml/min and the plasma clearance of antipyrine from 53.7 +/- 14.2 ml/min to 48.1 +/- 11.7 ml/min. Elimination half-life of theophylline was prolonged from 5.1 +/- 1.6 to 8.1 +/- 1.4 h. All these changes were statistically significant. Volume of distribution of theophylline (31.7 +/- 8.4 L before and 39.2 +/- 5.6 L during cimetidine administration) and plasma binding of theophylline (44.7 +/- 3.8% before and 44.3 +/- 3.1% during cimetidine administration) were not significantly different. Similarly, volume of distribution of antipyrine (45.8 +/- 14.0 vs. 47.6 +/- 17.9) was not significantly affected by cimetidine administration. We conclude that cimetidine impairs the elimination of theophylline and antipyrine in healthy subjects.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7239117

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  44 in total

Review 1.  Pharmacokinetic interactions between theophylline and other medication (Part II).

Authors:  R A Upton
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

2.  Drug interactions through binding to cytochrome p 450: the experience with h2-receptor blocking agents.

Authors:  U Klotz; I W Reimann
Journal:  Pharm Res       Date:  1984-03       Impact factor: 4.200

Review 3.  Nizatidine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease.

Authors:  A H Price; R N Brogden
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

Review 4.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 5.  Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

6.  The effect of ranitidine and cimetidine on imipramine disposition.

Authors:  B G Wells; J A Pieper; T H Self; C F Stewart; S L Waldon; L Bobo; C Warner
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  Inhibition of antipyrine metabolism by interferon.

Authors:  S J Williams; G C Farrell
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

8.  Femoxetine and cimetidine: interaction in healthy volunteers.

Authors:  J Schmidt; A S Sørensen; A Gjerris; O J Rafaelsen; H Mengel
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 9.  Theophylline poisoning. Pharmacological considerations and clinical management.

Authors:  P Gaudreault; J Guay
Journal:  Med Toxicol       Date:  1986 May-Jun

10.  Effect of cimetidine on digoxin disposition in peptic ulcer patients.

Authors:  M Garty; G Perry; H Shmueli; D Ilfeld; G Boner; S Pitlik; J Rosenfeld
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.